During the last session, Prothena Corporation plc (NASDAQ:PRTA)’s traded shares were 0.71 million, with the beta value of the company hitting 0.07. At the end of the trading day, the stock’s price was $12.79, reflecting an intraday loss of -7.39% or -$1.02. The 52-week high for the PRTA share is $41.54, that puts it down -224.78 from that peak though still a striking -3.36% loss since the share price plummeted to a 52-week low of $13.22. The company’s market capitalization is $688.21M, and the average intraday trading volume over the past 10 days was 0.44 million shares, and the average trade volume was 535.50K shares over the past three months.
Prothena Corporation plc (PRTA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. PRTA has a Sell rating from 1 analyst(s) out of 15 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.0.
Prothena Corporation plc (NASDAQ:PRTA) trade information
Prothena Corporation plc (PRTA) registered a -7.39% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -7.39% in intraday trading to $12.79, hitting a weekly high. The stock’s 5-day price performance is -8.97%, and it has moved by -25.77% in 30 days. Based on these gigs, the overall price performance for the year is -66.73%. The short interest in Prothena Corporation plc (NASDAQ:PRTA) is 8.06 million shares and it means that shorts have 17.35 day(s) to cover.
The consensus price target of analysts on Wall Street is $43, which implies an increase of 70.26% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $24 and $62 respectively. As a result, PRTA is trading at a discount of -384.75% off the target high and -87.65% off the low.
Prothena Corporation plc (PRTA) estimates and forecasts
Statistics show that Prothena Corporation plc has outperformed its competitors in share price, compared to the industry in which it operates. Prothena Corporation plc (PRTA) shares have gone down -37.33% during the last six months, with a year-to-date growth rate more than the industry average at 18.84% against 17.10. In the rating firms’ projections, revenue will increase 54.73% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 8.35M as predicted by 8 analyst(s). As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 316k and 50k respectively. In this case, analysts expect current quarter sales to grow by 2,542.37% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.83%. While earnings are projected to return 20.56% in 2024, the next five years will return 34.07% per annum.
PRTA Dividends
Prothena Corporation plc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Prothena Corporation plc (NASDAQ:PRTA)’s Major holders
Prothena Corporation plc insiders own 13.46% of total outstanding shares while institutional holders control 97.01%, with the float percentage being 112.09%. ECOR1 CAPITAL, LLC is the largest shareholder of the company, while 247.0 institutions own stock in it. As of 2024-06-30, the company held over 11.58 million shares (or 21.5666% of all shares), a total value of $239.1 million in shares.
The next largest institutional holding, with 8.07 million shares, is of FMR LLC’s that is approximately 15.016% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $166.48 million.
